RELMADA THERAPEUTICS, INC. (RLMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 08-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 3K 6K 9K FY12: 7.9K FY13: 5.1K FY12 FY13

Gross Profit Annual

0 800 1.6K 2.4K FY12: 2.1K FY13: 1.1K FY12 FY13

Operating Income Annual

-60K -40K -20K 0 20K 40K 60K FY12: -12.1K FY13: -45K FY12 FY13

Net Income Annual

-60K -40K -20K 0 20K 40K 60K FY12: -12.1K FY13: -45K FY12 FY13

Cost of Revenue Annual

0 2K 4K 6K FY12: 5.8K FY13: 4K FY12 FY13

Operating Cash Flow Annual

-15K -10K -5K 0 5K 10K 15K FY12: -7.6K FY13: -11.9K FY12 FY13

Free Cash Flow Annual

-15K -10K -5K 0 5K 10K 15K FY13: -13.7K FY13

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q1 '22: -6.63 Q2 '22: -7.14 Q3 '22: -7.20 Q4 '22: -6.97 Q1 '23: -5.84 Q2 '23: -5.30 Q3 '23: -4.77 Q4 '23: -4.28 Q1 '24: -3.70 Q2 '24: -3.27 Q3 '24: -3.12 Q4 '24: -2.87 Q1 '25: -2.86 Q2 '25: -2.65 Q3 '25: -2.51 Q4 '25: -2.22 Q1 '26: -1.80 Q2 '26: -1.47 Q3 '26: -1.11 Q4 '26: -0.92 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26 Q4 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.